Major depressive disorders pipeline: insights into leadership

0

Los Angeles, United States, Aug 25, 2021 (GLOBE NEWSWIRE) – Major Depressive Disorders Pipeline: Overview of Major Pharmaceutical Players, New Emerging Therapies, Clinical Trials and Future Perspectives | SearchInsight

The Major Depressive Disorders pipeline is evolving with new therapies as well as reoriented therapies in the pipeline, as well as a better understanding of the mechanisms of action.

DelveInsight’s Overview of the major depressive disorder (MDD) pipeline The report offers comprehensive coverage of the emerging therapeutic landscape at different stages of development, from preclinical to late stage, as well as dormant, inactive and abandoned therapeutic agents.

The Major Depressive Disorders Pipeline Reports provide a comprehensive picture of ongoing clinical trials, ongoing partnerships in the field, recent events in the space, and prospects for growth in the field of major depressive disorders.

Some of the highlights of the Major depressive disorders pipeline report:

  • The Major Depressive Disorders Pipeline report provides a rich analysis of 75+ key players and 75+ key therapies.
  • The Major Depressive Disorders pipeline includes therapies at different stages of the clinical phase, such as: Vraylar, PDC-1421, AV-101, AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, Lumateperone, and others, and many more are expected to enter the private label market over the next decade.
  • Some of the key companies engaged in strengthening the major depressive disorders pipeline are Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, among others.
  • In June 2021, Sage Therapeutics and Biogen announced the Phase III results of Zuranolone (WATERFALL study). The study met its primary endpoint, on day 15 zuranolone 50 mg showed a statistically significant and clinically significant reduction in depressive symptoms as measured by HAMD-17 (p = 0.0141) compared to placebo .
  • In June 2021, Small Pharma announced the extension of its Phase I / IIa clinical trial for its flagship product, SPL026, an N, N-dimethyltryptamine (“DMT”) treatment for major depressive disorder.

Sample request to learn more about therapies set to capture maximum patients @ Emerging therapies and predictions for major depressive disorder

Major depressive disorder (MDD) is one of the most common psychiatric disorders that results in persistent sadness, loss of interest or pleasure, lack of energy, decreased appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions. It is the main cause of the disease burden in high income countries.

For more information on emerging drugs, visit Major depressive disorder pipeline analysis

Drugs in the pipeline for major depressive disorder

Medication Society Phase MoA RdA
Vraylar Allergan / Gedeon Richter Phase III Partial dopamine D2 receptor agonists Oral
PDC-1421 Biolite inc. Phase II Plasma membrane transport protein norepinephrine inhibitors Oral
AV-101 VistaGen Therapeutics Phase II NMDA receptor modulators Oral
AXS-05 Axsome Therapeutics Pre-registration Adrenergic receptor antagonists Oral
Pramipexole Therapeutic chase Phase II Dopamine D2 receptor agonists Oral
SAGE-217 Therapeutic sage Phase III GABA A receptor modulators Oral
LY03005 Luye Pharma Group Pre-registration Serotonin uptake inhibitors Oral
Seltorexant Minerva Therapeutics Phase III Orexin type 2 receptor antagonists Oral
PH10 VistaGen Therapeutics Phase II Cellular chemoreceptor stimulants Intranasal
PRAX-114 Praxis Precision Medicines Phase II / III GABA modulators Oral
REL-1017 Relmada Therapeutic Phase III NMDA receptor antagonists Oral
Caplyta Intracellular therapies Phase III Glutamate modulator Oral

Sample request to find out more @ Major Depressive Disorders Pipeline Analysis, Key Companies and Futuristic Trends

Therapeutic evaluation of major depressive disorder

The Major Depressive Disorders Pipeline report offers in-depth information of the active pipeline assets segmented by stage, product type, route of administration, molecule type, target, and mechanism of action.

By product type

By step

  • Discovery
  • Pre-clinic
  • INDIANA
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By molecule type

  • Bispecific antibody
  • Peptides
  • Small molecule
  • Genetical therapy

By route of administration

  • Oral
  • Subcutaneous
  • Intranasal
  • Intramuscular

By mechanism of action

  • Dopamine D2 receptor agonist
  • Serotonin 1A receptor agonists
  • Glutamate modulator
  • NMDA receptor modulators
  • Adrenergic receptor antagonists
  • GABA A receptor modulators
  • Orexin type 2 receptor antagonists

By targets

  • Dopamine D2 receptor
  • Serotonin 1A receptor
  • Glutamate
  • NMDA receiver
  • Adrenergic receptor
  • GABAA receiver
  • Type 2 orexin receptor

Contact our sales manager for Informative business decisions, licensing services and consulting solutions

Scope of the report

Blanket: Global
Key players: Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Gedeon Richter, Small Pharma, Clexio Biosciences, VistaGen Therapeutics, among others.

Key pipeline therapies for major depressive disorder: Vraylar, PDC-1421, AV-101, AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, Cariprazine, SPL026, CLE-100, among others.

To reach @ Major depressive disorders pipeline: new therapies and emerging technologies

Contents

1 Presentation of the report
2 Major depressive disorder illness overview
3 Prospects for the Major Depressive Disorders Pipeline
4 Comparative analysis
5 Therapeutics for Clinical Major Depressive Disorder
6 Therapeutics for non-clinical major depressive disorder
7 Analysis of the therapeutic pipeline for major depressive disorder
8 Inactive Major Depressive Disorders Pipeline Products
9 Annex
ten Methodology of the report
11 Consulting services
12 Disclaimer
13 About DelveInsight

Visit to learn more about what’s covered @ Major depressive disorders Emerging therapies, treatments and ongoing clinical trials

Associated reports

Complex Regional Pain Syndrome Market
DelveInsight’s’Complex Regional Pain Syndrome (CRPS) Market Overview, Epidemiology and Market Forecast-2030‘ report.

Concussion Market
DelveInsight’s “Concussion Market Overview, Epidemiology and Market Forecast-2030” report.

Memory Disorders Market
DelveInsight’s “Memory Disorders – Market Overview, Epidemiology, and Market Forecast-2030” report.

Multiple Organ Dysfunction Syndrome Market
DelveInsight’s “Multiple Organ Dysfunction Syndrome Market Overview, Epidemiology and Market Forecast-2030” report.

Multiple Sclerosis Market
DelveInsight’s “Multiple Sclerosis Market Overview, Epidemiology and Market Forecast-2030” report.

Drug overdose market
DelveInsight’s ” Drug Overdose – Market Overview, Epidemiology and Market Forecast-2030” report.

Narcolepsy market
DelveInsight’s’Narcolepsy Market Overview, Epidemiology and Market Forecast-2030‘ report..

Bipolar Disorder (Manic Depression) Market
DelveInsight’s’Bipolar Disorder (Manic Depression) – Market Overview, Epidemiology and Market Forecast-2030‘ report.

Postpartum Depression Market
DelveInsight report on “Postpartum Depression (PPD) – Market Overview, Epidemiology and Market Forecast – 2030”.

Treatment Resistant Depression Market
DelveInsight’s “Treatment Resistant Depression Market Overview, Epidemiology and Market Forecast-2030“report offer.

Suggested reading

Mental health issues
Bipolar Depression Market
Depression and societal mental health
Schizophrenia market dynamics

On SearchInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical market research reports through our subscription platform PharmaDelve.

For more information visit Pharmaceutical, medical and biotechnology news


        


Source link

Leave A Reply

Your email address will not be published.